United States Medical Isotope Production Market Size, Share, Growth, and Industry Analysis, By Isotope Type (Diagnostic Isotopes, Therapeutic Isotopes), By Production Technology (Nuclear Reactor-Based Production, Fission-based, Neutron activation, Cyclotron-Based Production) and Forecast, 2026-2034

United States Medical Isotope Production Market Trends

Domestic Supply Localization and Accelerator-Based Production

Domestic production capacity is moving higher on the strategic agenda as hospitals remain exposed to short-lived isotope supply disruptions. Mo-99 supports approximately 40,000 U.S. medical administrations daily, equivalent to more than 14 million annual administrations at that run rate. A separate 2026 technical assessment places annual U.S. Tc-99m diagnostic procedures above 16 million. New high-current deuteron cyclotron concepts target approximately 10^13 neutrons per second using a 5 mA beam, illustrating the technological push toward more distributed production.

Technology development increasingly combines reactor, accelerator, fission, neutron-activation, and fusion-linked pathways. In April 2026, DOE announced a conditional commitment of up to USD 263 million for SHINE’s Wisconsin facility, following federal support intended to reduce reliance on imported Mo-99. The facility is designed around fusion and fission technology, while earlier federal reporting indicated construction was approximately 75% complete in 2025.

United States Medical Isotope Production Market Drivers

High Diagnostic Utilization and Expanding Nuclear Medicine Infrastructure

Demand is supported by the recurring clinical use of Tc-99m and other isotopes across oncology, cardiology, neurology, and organ-function imaging. Mo-99-derived products are administered around 40,000 times per day in the United States, while estimates exceed 16 million Tc-99m diagnostic procedures annually. Federal measures also include a USD 10 Medicare add-on payment proposed for qualifying radiopharmaceuticals derived from domestically produced Mo-99 beginning in 2026, strengthening the commercial rationale for U.S.-based capacity.

United States Medical Isotope Production Market Restraints

Capital Intensity, Regulatory Complexity, and Short Isotope Half-Lives

Production requires specialized reactors, accelerators, hot cells, enriched targets, processing equipment, transportation systems, and radiation controls. SHINE’s facility was reported approximately 75% complete in 2025, yet commercialization required additional federal support, including USD 32 million identified by NNSA and a subsequent conditional DOE financing commitment of up to USD 263 million in 2026. These figures demonstrate the substantial capital burden associated with moving isotope capacity from construction through reliable commercial operation.

United States Medical Isotope Production Market Opportunities

Reshoring Mo-99 and Scaling Therapeutic Radioisotope Platforms

Supply-chain localization creates opportunities across Mo-99/Tc-99m and emerging therapeutic isotopes. The 2024 simultaneous shutdown of 2 overseas production reactors contributed to a major Mo-99 shortage affecting U.S. healthcare, strengthening the case for diversified domestic capacity. Government support includes USD 32 million identified for SHINE in 2025 and conditional financing of up to USD 263 million announced in April 2026. Expansion into fusion, fission, cyclotron, and neutron-driven platforms could reduce import dependence while supporting millions of diagnostic and therapeutic procedures.

Challanges in United States Medical Isotope Production Market

Balancing Production Reliability with Commercial Economics

The principal challenge is establishing economically sustainable production while maintaining uninterrupted clinical supply. Mo-99 supports approximately 40,000 U.S. administrations each day, making even short disruptions material to hospitals and imaging centers. The 2024 shortage demonstrated this exposure when 2 foreign reactors were simultaneously unavailable. At the same time, federal support reaching USD 263 million for one major domestic project illustrates the scale of financing potentially required to establish new high-volume capacity.

United States Medical Isotope Production Market Segmentation

The industry is segmented by isotope type, production technology, application, and end user. Diagnostic isotopes dominate the supplied isotope dataset with approximately 55.4% of 2026 revenue, while therapeutic isotopes represent about 44.6%. Within the reported technology categories, nuclear reactor-based production reaches USD 516.82 million in 2026, whereas cyclotron-based production reaches USD 207.42 million.

By Isotope Type

Diagnostic isotopes are the largest category, increasing from USD 737.29 million in 2025 to USD 797.75 million in 2026 and USD 1,498.59 million by 2034, representing an 8.20% CAGR. Their approximately 55.4% contribution in 2026 reflects extensive utilization in functional imaging and disease diagnosis.

Therapeutic isotopes increase from USD 592.11 million in 2025 to USD 641.61 million in 2026 and USD 1,219.62 million by 2034. At 8.36% CAGR, therapeutic isotopes are the faster-growing isotope category, supported by targeted radionuclide therapy and oncology applications.

By Production Technology

Nuclear reactor-based production is the largest explicitly reported technology category, rising from USD 478.58 million in 2025 to USD 516.82 million in 2026 and USD 955.89 million by 2034 at a 7.99% CAGR. Fission-based production reaches USD 297.87 million in 2026 and USD 576.75 million by 2034 at 8.61%.

Neutron activation posts the fastest stated technology CAGR of 8.64%, moving from USD 205.66 million in 2025 to USD 223.43 million in 2026 and USD 433.57 million by 2034. Cyclotron-based production reaches USD 379.12 million by 2034 at 7.83%, proton acceleration reaches USD 224.03 million at 8.00%, and deuteron-based reactions reach USD 139.78 million at 8.61%.

By Application

Diagnostic applications represent a central utilization channel, consistent with diagnostic isotopes generating approximately 55.4% of 2026 isotope-type revenue. Therapeutic and research applications are gaining importance alongside radioligand therapy and isotope-development programs; however, the supplied mandatory dataset does not provide independent application-level revenue or CAGR values, so no additional market values have been inferred.

Clinical demand is reinforced by approximately 40,000 daily U.S. administrations associated with Mo-99-derived diagnostic products and more than 16 million annual Tc-99m diagnostic procedures reported in technical literature. Therapeutic adoption is simultaneously encouraging production investment in isotopes suited to targeted cancer treatment.

By End-User

Hospitals and clinics constitute a core consumption channel because isotope-based procedures require continuous access to time-sensitive radiopharmaceuticals. Diagnostic imaging centers represent another major user group, while academic institutes, pharmaceutical and biotechnology companies, and CROs support isotope research, clinical development, dosimetry, and next-generation radiopharmaceutical programs.

End-user-specific revenue and CAGR figures were not provided in the mandatory tables and are therefore not estimated. Operational scale is nevertheless significant: approximately 40,000 daily U.S. Mo-99-related administrations translate into more than 14 million procedures annually at a constant daily rate, illustrating the logistical intensity facing hospitals, pharmacies, producers, and distributors.

United States Medical Isotope Production Market Outlook

Wisconsin represents a strategically important production cluster through projects in Janesville and Beloit. SHINE’s Janesville project was approximately 75% complete according to September 2025 federal reporting and received a conditional financing commitment of up to USD 263 million in April 2026. NorthStar has also developed Mo-99 production infrastructure in Beloit.

Missouri is another relevant production location through the University of Missouri Research Reactor and associated isotope programs, while national laboratories and accelerator facilities contribute research and specialty-isotope capacity across additional states. Numerical county/state shares, production revenue, and CAGR were not supplied in the mandatory dataset; consequently, regional percentage contributions are not fabricated or extrapolated from the national USD 1,439.36 million 2026 total.

Top players in United States Medical Isotope Production Market

• Curium
• NorthStar Medical Radioisotopes
• SHINE Technologies
• BWXT Medical
• Lantheus Holdings
• Cardinal Health
• GE HealthCare
• Jubilant Radiopharma
• Eckert & Ziegler
• International Isotopes
• Niowave
• ASP Isotopes
• Atomic Alchemy
• University of Missouri Research Reactor
• National Isotope Development Center

Top Two Companies

• SHINE Technologies

SHINE occupies a prominent emerging position in U.S. domestic Mo-99 infrastructure. Its Janesville production facility was reported approximately 75% complete in 2025, with NNSA identifying USD 32 million in additional support. In April 2026, DOE issued a conditional commitment for financing of up to USD 263 million to support the high-volume facility. The project uses fusion and fission-related technology and is strategically positioned around reshoring a medical isotope historically dependent on foreign supply. A verified company percentage revenue share is not publicly established in the supplied dataset and therefore is not estimated.

• NorthStar Medical Radioisotopes

NorthStar is positioned as an important U.S. participant in non-HEU Mo-99 production infrastructure. Its Beloit, Wisconsin facility was developed with electron-accelerator-based technology as part of federal efforts to establish domestic Mo-99 supply. Mo-99 supports more than 40,000 U.S. diagnostic administrations per day, giving domestic production assets strategic importance for nuclear medicine availability. NorthStar’s exact percentage share of U.S. production revenue is not included in the mandatory tables or authoritative sources reviewed and is therefore not assigned an unsupported numerical share.

Recent Developments in United States Medical Isotope Production Market

• 2026:DOE announced a conditional commitment for a loan of up toUSD 263 millionto SHINE Chrysalis for construction of its high-volume Janesville medical-isotope facility.
• 2026:The NRC approved direct transfer of SHINE Medical Isotope Production Facility Construction PermitCPMIF-001to SHINE Chrysalis, supporting restructuring of the project ahead of further development.
• 2026:DOE isotope programs reported advances in domestic isotope supply chains, including enrichment capabilities delivering certain stable isotopes at least100×more depleted of contaminants than commercial alternatives.
• 2025:NNSA identifiedUSD 32 millionin support for SHINE’s approximately75% completedMo-99 production facility, while CMS proposed aUSD 10add-on payment for eligible domestically sourced Mo-99-derived radiopharmaceuticals from 2026.
• 2024–2025:A simultaneous outage involving2 overseas reactorstriggered a major Mo-99 shortage affecting U.S. supply, reinforcing federal and commercial efforts to diversify domestic production capacity.

Research Methodology

The assessment uses the supplied mandatory numerical tables as the controlling source for 2025, 2026, 2034, segment revenue, percentage contribution, and CAGR calculations. The primary forecast advances from USD 1,439.36 million in 2026 to USD 2,718.21 million in 2034 at 8.28% CAGR. Segment shares were calculated directly from supplied totals; for example, USD 797.75 million of diagnostic-isotope revenue represents approximately 55.4% of the USD 1,439.36 million 2026 isotope total. External authoritative information was restricted to qualitative industry context, production activity, government financing, clinical utilization, and recent developments. No unsupported state, county, application, end-user, or company percentage values were created where the mandatory dataset did not provide sufficient numerical evidence.